NCT03193866View on ClinicalTrials.gov

COMparison Between All immunoTherapies for Multiple Sclerosis.

CompletedOBSERVATIONAL
Enrollment

3,526

Participants

Timeline

Start Date

June 2, 2017

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

Rituximab

Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis

Trial Locations (1)

Unknown

Fredrik Piehl, Stockholm

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

Kaiser Foundation Research Institute

OTHER

lead

Karolinska Institutet

OTHER

NCT03193866 - COMparison Between All immunoTherapies for Multiple Sclerosis. | Biotech Hunter | Biotech Hunter